NCT07313332 Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation
| NCT ID | NCT07313332 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Nottingham |
| Condition | Healthy Adult Male and Female Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 14 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 14 participants in total. It began in 2026-01-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colorectal cancer is the fourth most common cancer in the UK. Prehabilitation, including exercise, can improve recovery from surgery. This pilot study investigates the combined effects of resistance and high-intensity interval training (ReHIIT) in healthy adults to establish baseline physiology and responses for comparison with cancer patients
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Availability and willingness to attend the Royal Derby Hospital site for a minimum of 8 exercise sessions and 2 assessment sessions across the study period. Exclusion Criteria: * BMI \<18 or \>35 kg/m2 * Known active cance * Known metabolic disease * Current known neurological or musculoskeletal conditions (e.g. epilepsy) * Active known cardiovascular, cerebrovascular or respiratory disease - e.g: * Uncontrolled hypertension (systolic BP \> 160 mmHg or diastolic BP \>100 mmhg) * Myocardial infarction within the last 6 months or unstable angina * Heart failure (New York Heart association Class III/IV) * Arrhythmia * Right to left cardiac shunt * Aneurysm of a named blood vessel * COPD * Pulmonary hypertension * Exercise-induced or brittle asthma * Previous stroke/transient ischaemic attack * Abnormal ECG results (at the discrepancy of the study doctor) * Patients who are unable to undergo CPET based on ATS/ACSS guidelines \^ * Pre-existing clotting disorder known to the participant or anticoagulant use * Family history of severe bleeding requiring medical intervention * Participation in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (ALL UoN FMHS UREC approved studies) * Pregnant or breastfeeding
Contact & Investigator
Professor Bethan E Phillips
PRINCIPAL INVESTIGATOR
University of Nottingham
Frequently Asked Questions
Who can join the NCT07313332 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Adult Male and Female Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07313332 currently recruiting?
Yes, NCT07313332 is actively recruiting participants. Contact the research team at tyler.daubrah-scott@nottingham.ac.uk for enrollment information.
Where is the NCT07313332 trial being conducted?
This trial is being conducted at Derby, United Kingdom.
Who is sponsoring the NCT07313332 clinical trial?
NCT07313332 is sponsored by University of Nottingham. The principal investigator is Professor Bethan E Phillips at University of Nottingham. The trial plans to enroll 14 participants.